We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips (PHG) Launches OncoSuite to Improve Oncology Care
Read MoreHide Full Article
Koninklijke Philips N.V. (PHG - Free Report) recently expanded its healthcare portfolio with the launch of OncoSuite, a state-of-the-art interventional oncology solution. This will be unveiled at the Cardiovascular and Interventional Radiological Society of Europe’s annual meet (“CIRSE”), being held at Barcelona from Sep 10–14.
With the launch of OncoSuite, Philips is pioneering the development of both tumor embolization and ablation procedures, which will aid physicians to treat multiple tumor lesions simultaneously. It is built on Philips’ interventional X-ray systems and can offer enhanced imaging, live 3D image guidance for tumor embolization and 3D image guidance for tumor ablation. It will also help physicians to improve their decision making while performing these complicated procedures.
This launch also reflects the company’s goal to expand its minimally-invasive treatment techniques that have been steadily gaining popularity in the healthcare domain. OncoSuite is a breakthrough development in interventional radiology to treat patients on whom procedures like surgery, chemotherapy or radiation therapy could not be performed. It helps physicians to gain a better view of targeted areas and treat tumor lesions by reducing the impact on healthy tissue.
With instances of non-alcoholic fatty liver diseases on rise, Philips believes there is a pressing need for technologies like OncoSuite that can offer optimal care for patients at affordable prices. As a matter of fact, Philips is gradually evolving as a healthcare company. It has grown its presence in the healthcare domain over the past couple of quarters. Especially, the company’s Diagnosis & Treatment vertical is showing significant promise on account of positive industry trends like thriving Image-Guided Therapy and Ultrasound equipment sales.
We believe that Philips’ comprehensive healthcare portfolio with increased expenditure on healthcare is a signal for brighter days emerging for the company. Particularly, higher level of quality and regulatory expenditure in the second half of 2016, and first half of 2017, are likely to bolster growth in this vertical.
Interested in IPOs? Check out the special edition of Zacks Friday Finish Line below, where Editor Maddy Johnson and Content Writer Ryan McQueeney interview Kathleen Smith of Renaissance Capital about the IPO market in 2016 (see part two here).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Philips (PHG) Launches OncoSuite to Improve Oncology Care
Koninklijke Philips N.V. (PHG - Free Report) recently expanded its healthcare portfolio with the launch of OncoSuite, a state-of-the-art interventional oncology solution. This will be unveiled at the Cardiovascular and Interventional Radiological Society of Europe’s annual meet (“CIRSE”), being held at Barcelona from Sep 10–14.
With the launch of OncoSuite, Philips is pioneering the development of both tumor embolization and ablation procedures, which will aid physicians to treat multiple tumor lesions simultaneously. It is built on Philips’ interventional X-ray systems and can offer enhanced imaging, live 3D image guidance for tumor embolization and 3D image guidance for tumor ablation. It will also help physicians to improve their decision making while performing these complicated procedures.
This launch also reflects the company’s goal to expand its minimally-invasive treatment techniques that have been steadily gaining popularity in the healthcare domain. OncoSuite is a breakthrough development in interventional radiology to treat patients on whom procedures like surgery, chemotherapy or radiation therapy could not be performed. It helps physicians to gain a better view of targeted areas and treat tumor lesions by reducing the impact on healthy tissue.
With instances of non-alcoholic fatty liver diseases on rise, Philips believes there is a pressing need for technologies like OncoSuite that can offer optimal care for patients at affordable prices. As a matter of fact, Philips is gradually evolving as a healthcare company. It has grown its presence in the healthcare domain over the past couple of quarters. Especially, the company’s Diagnosis & Treatment vertical is showing significant promise on account of positive industry trends like thriving Image-Guided Therapy and Ultrasound equipment sales.
KONINKLIJKE PHL Price
KONINKLIJKE PHL Price | KONINKLIJKE PHL Quote
We believe that Philips’ comprehensive healthcare portfolio with increased expenditure on healthcare is a signal for brighter days emerging for the company. Particularly, higher level of quality and regulatory expenditure in the second half of 2016, and first half of 2017, are likely to bolster growth in this vertical.
Philips currently holds a Zacks Rank #2 (Buy). Other favorably placed stocks in the industry include Daktronics Inc. (DAKT - Free Report) , Garmin Ltd. (GRMN - Free Report) and Amkor Technology, Inc. (AMKR - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Interested in IPOs? Check out the special edition of Zacks Friday Finish Line below, where Editor Maddy Johnson and Content Writer Ryan McQueeney interview Kathleen Smith of Renaissance Capital about the IPO market in 2016 (see part two here).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>